||WZ811 is a novel and effective small molecular CXCR4 antagonist (EC50: 0.3 nM).
||Plerixafor, a chemokine receptor antagonist, blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4.
||AMD 3100 octahydrochloride
||AMD 3100 octahydrochloride blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation. Plerixafor is a bicyclam with hematopoietic stem cell-mobili
||SB225002 is a potent and selective CXCR2 antagonist inhibiting interleukin IL-8 binding to CXCR2.
||UNBS-5162 is a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers.
||SRT3109 is a CXCR2 ligand used in the treatment of chemokine mediated diseases and conditions.
||Arteether is a new, fast-acting antimalarial drug.
||Baohuoside I is a component of Epimedium koreanum, exhibits anti-inflammatory activity and anti-osteoporosis activities.
||MSX-127 elicites positive response in peptide CXCR4.
||MSX-130 is CXCR4 Antagonist.
||Reparixin is a potent inhibitor of both CXCL8 receptors?CXCR1/2, it inhibits weakly?CXCR2-mediated cell migration (IC50=100 nM), whereas it strongly blocks?CXCR1-mediated chemotaxis (IC50=1 nM).
||ATI-2341, pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is an allosteric agonist activating the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization.